Bioventix is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.
Missing: Bioventix's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Bioventix's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Bioventix
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Bioventix is included in 1 Expert Collection, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Latest Bioventix News
Dec 29, 2022
Bioventix PLC 4100.00 12/29/2022 | 10:04am EST Message : 1. Issuer Details 3. Details of person subject to the notification obligation Name Country of registered office (if applicable) GB Name 28-Dec-2022 29-Dec-2022 . % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer Resulting situation on the date on which threshold was crossed or reached 11.004000 10.982000 11.004000 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached 8A. Voting rights attached to shares Class/Type of shares ISIN code(if possible) Number of direct voting rights (DTR5.1) Number of indirect voting rights (DTR5.2.1) % of direct voting rights (DTR5.1) % of indirect voting rights (DTR5.2.1) GB00B4QVDF07
Bioventix Frequently Asked Questions (FAQ)
Where is Bioventix's headquarters?
Bioventix's headquarters is located at 7 Romans Business Park, Surrey.
What is Bioventix's latest funding round?
Bioventix's latest funding round is Other Investors.
Who are the investors of Bioventix?
Investors of Bioventix include SpringHill Management.
Who are Bioventix's competitors?
Competitors of Bioventix include F-star Therapeutics, Gliknik, Amplyx Pharmaceuticals, InvivoSciences, HTG Molecular Diagnostics and 11 more.
Compare Bioventix to Competitors
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Thermalin engineers new forms of insulin that will lower the burden of insulin use, increase patient adoption of and adherence to insulin therapy, improve patient lives and outcomes, and lower the cost of caring for people with Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).
Adimab is engaged in the discovery, maturation and production of therapeutic human antibodies. Per the company, Adimab integrates all aspects of antibody discovery and sophisticated screening methods, and therefore can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. The company states that their proprietary library design and presentation technology allows Adimab to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology.
Altus is focused on accelerating the development and commercialization of protein-based products through our Crystalomics technology platform. Crystalomics aims to rapidly turn proteins into products resulting in significant market benefits in Therapeutic, Diagnostic, and Industrial applications.
SIRS-Lab with its diagnostic portfolio! VYOO Sepsis Test is a multiplex pcr detection kit to identifiy bacteria and fungi in whole blood! LOOXSTER sample preparation kit concentrates bacterial and fungal DNA! With expert knowledge in molecular diagnostic, critical care medicine, microbiology, assay design and gene expression service!
Entegrion is a life sciences development company specializing in technologies that support preserve the function of the human vascular system. The company's technologies are designed to overcome limitations in temperature, storage, safety, and availability of blood-derived products while improving functionality. The company was founded in 2002 and is based in Durham, North Carolina.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.